Seald AS is a biotech company developing an innovative personalized approach to treating bile duct cancer. Bile duct cancer is a rare, but very deadly form of cancer. The five-year survival rate is two to five per cent, the mean life expectancy on standard chemotherapy is only 11,5 months. A small number of patients are eligible for surgery, and more than 50 per cent of these relaps.

Our innovative and holistic approach to cures and biomarkers combines drug sensitivity screening on patients own living cancer cells, analyses and sequencing on fresh biopsies, seamless data-integration and exclusive test treatment on living patient-avatar.

The constellation Cancer in our logo symbolizes our innovative and multidisciplinary approach.